REGENERON REPORTS POSITIVE PHASE 1 DATA FOR THE VEGF TRAP IN AGE-RELATED MACULAR DEGENERATION Preliminary results show improvements in vision and retinal swelling VEGF Trap was well tolerated at all dose levels Company also announces initiation of phase 2 trial
Tuesday, May 2, 2006 BiopharmaWatch Research 1 min read
Key Takeaway: REGENERON REPORTS POSITIVE PHASE 1 DATA FOR THE VEGF TRAP IN AGE-RELATED MACULAR DEGENERATION Preliminary results show improvements in vision and retinal swelling VEGF Trap was well tolerated at all dose levels Company also announces initiation of phase 2 trial
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema
Full Press Release Details
REGENERON REPORTS POSITIVE PHASE 1 DATA FOR THE VEGF TRAP IN AGE-RELATED MACULAR DEGENERATION Preliminary results show improvements in vision and retinal swelling VEGF Trap was well tolerated at all dose levels Company also announces initiation of phase 2 trial.